Combined analysis of chromatin accessibility, promoter interactions and whole genome sequencing solved the missing heritability in gastric cancer

By integrating whole-genome sequencing with stomach-specific chromatin accessibility and promoter interaction analyses, this study identified novel oligogenic mechanisms involving deletions of regulatory elements in the CDH1 and MLH1 loci, as well as immune and mucin-related pathways, that explain the missing heritability in 47% of hereditary diffuse gastric cancer-like families.

The Gist

Imagine your body is a massive, bustling city. In this city, there are specific "construction crews" (genes) responsible for keeping the buildings (cells) stable and connected. One of the most important crews is the CDH1 team, which acts like the mortar holding the bricks of your stomach lining together. If this mortar fails, the wall crumbles, and cancer can start.

For years, doctors have been looking for the "blueprint errors" (genetic mutations) that cause a specific, aggressive type of stomach cancer called Hereditary Diffuse Gastric Cancer (HDGC). They knew that in many families, the disease ran in the bloodline, but when they checked the main blueprints (the known genes CDH1 and CTNNA1), they found nothing wrong. It was like looking for a broken brick in a wall that looked perfectly fine, yet the wall was still collapsing. This mystery is called "missing heritability"—the gap between the family history of cancer and the genetic clues doctors could actually find.

The Detective Work: Looking Beyond the Obvious

In this study, researchers decided to stop looking just at the main blueprints and started inspecting the entire construction site, including the power lines, the traffic lights, and the remote control switches that tell the construction crews when to work.

They used a high-tech "flashlight" (Whole Genome Sequencing) to scan the DNA of 19 families who had the cancer but no obvious genetic cause. But a flashlight isn't enough; they also needed to see how the city was organized. They mapped out:

• Chromatin Accessibility: Which parts of the DNA are "open" and ready to be read? (Like open doors vs. locked rooms).
• Promoter Interactions: How do the switches talk to the construction crews? (Like a remote control sending a signal to a lightbulb).

The Big Discoveries: It's Not Just the Brick, It's the Switch

The researchers found that the problem wasn't always a broken brick (a mutation in the gene itself). Often, the problem was that the switches controlling the brick-laying crew had been smashed or removed.

Here are the three main "smoking guns" they found:

1. The "Remote Control" Deletion (Family F4 & F9)
Imagine the CDH1 gene is a lightbulb. Usually, there are two switches (one from mom, one from dad) to turn it on.

• In Family F4, researchers found a 20,000-letter chunk of DNA missing. This chunk contained two tiny "dimmer switches" (regulatory elements) that told the CDH1 gene how much light to shine. Without these switches, the gene went dark, even though the lightbulb itself was perfect.
• In Family F9, a tiny 39-letter piece of DNA was missing just downstream. It was like cutting the wire to the switch. Again, the lightbulb (CDH1) went dark, causing the stomach wall to crumble.

2. The "Cross-Talk" Glitch (Family F15)
This family had a missing piece of DNA near a different gene called MLH1 (which usually fixes DNA errors).

• The researchers found that this missing piece was a switch specifically for the stomach. When it broke, it didn't just stop MLH1 from working; it accidentally turned off the CDH1 lightbulb too! It was like a power surge in one part of the city that accidentally shut down the lights in a completely different building. This explained why these patients got stomach cancer but not the other types of cancer usually linked to MLH1.

3. The "City-Wide Blackout" (The Oligogenic Pattern)
In several other families, the researchers didn't find just one broken switch. Instead, they found multiple small deletions scattered across the stomach's DNA.

• Think of this as a city-wide power outage where several different power lines were cut. This didn't just affect the CDH1 crew; it knocked out the "mucin" crew (which makes protective slime) and the "immune" crew (which fights off bad guys). The result? A stomach that is defenseless, dry, and easy for cancer to invade.

The Solution: Putting the Puzzle Together

By combining the "blueprint" (DNA sequence) with the "city map" (how the DNA is organized and accessed), the researchers finally solved the mystery.

They found that 47% of the families who previously had no explanation for their cancer actually had these hidden "switch" deletions.

Why This Matters

Before this study, families with this cancer were told, "We don't know why you have this, so we can't offer you special prevention." It was like being told, "Your car is broken, but since we can't find the engine part, we can't fix it."

Now, doctors know that the "engine" might be fine, but the ignition switch is missing. This means:

1. Diagnosis: They can now test for these specific "switch" deletions.
2. Prevention: Families can finally be offered life-saving measures, like regular screenings or preventative surgery, because the cause has been identified.
3. Hope: They solved the "missing heritability" for nearly half of the families who were left in the dark.

In short, the researchers stopped looking for a broken brick and started looking for the missing switches, finally turning the lights back on for families suffering from this mysterious disease.

Technical Summary

Technical Summary: Combined Analysis of Chromatin Accessibility, Promoter Interactions, and WGS in HDGC

1. Problem Statement

Hereditary Diffuse Gastric Cancer (HDGC) is a severe hereditary syndrome typically caused by germline mutations in CDH1 (E-cadherin) or CTNNA1. However, a significant proportion of families meeting clinical HDGC criteria ("HDGC-like families") lack actionable germline variants in these known genes. This phenomenon, known as "missing heritability," affects 60–90% of such cases, leaving these high-risk individuals without targeted life-saving prevention measures. The study aims to identify novel predisposition mechanisms, specifically focusing on non-coding regulatory variants and structural variations that disrupt the CDH1 regulatory network and other gastric cancer pathways.

2. Methodology

The researchers employed a multi-omics approach integrating genomic, epigenomic, and functional validation techniques:

• Genomic Sequencing & Variant Calling: Whole-genome sequencing (WGS) was performed on 19 HDGC-like probands. Single-nucleotide variants (SNVs) and copy-number variants (CNVs) were called, followed by gene-ontology analysis.
• Epigenomic Mapping: To define regulatory landscapes, the team utilized:
  • ChIP-seq: To map chromatin enhancer marks.
  • ATAC-seq: To assess chromatin accessibility in normal stomach tissue.
  • 4C-seq: To evaluate promoter interactions and Topologically Associating Domains (TADs) specifically around the CDH1 locus.
• Tumor Characterization: Patient tumors were analyzed via RT-PCR, immunohistochemistry (IHC), and Microsatellite Instability (MSI) analysis to correlate germline findings with somatic phenotypes.
• Functional Validation:
  • CRISPR-Cas9: Used in cell lines to mimic specific deletions and assess their impact on gene expression.
  • Flow Cytometry & RT-PCR: To quantify protein and mRNA levels.
  • Enhancer Assays: Conducted in mouse embryos to test tissue-specific regulatory activity.

3. Key Contributions & Results

The study successfully identified novel germline mechanisms explaining the missing heritability in 47% of the HDGC-like families within the cohort. The findings are categorized into three primary mechanisms:

A. Disruption of CDH1 Regulatory Elements within its TAD

• Family F4: Identified a heterozygous 20kb deletion in CDH3 (within the CDH1 TAD). This deletion removed two hypomorphic, tissue-specific regulatory elements (REs). Functional assays showed that each RE contributes 50% to CDH1 expression. The deletion triggered a loss of CDH1 mRNA and protein, phenocopying a coding deletion.
• Family F9: Identified a heterozygous 39bp intergenic CNV downstream of CDH1. CRISPR-Cas9 editing confirmed this variant triggers CDH1 mRNA/protein loss.

B. Disruption of MLH1 Regulatory Elements Affecting CDH1

• Family F15: A patient with gastric (but not colorectal) cancer carried a heterozygous 2.7kb germline CNV in MLH1 overlapping a stomach-specific RE identified by ChIP-seq.
• Phenotype: The tumor exhibited Microsatellite Instability (MSI), reduced MLH1 expression, and a concurrent reduction in CDH1/E-cadherin.
• Mechanism: CRISPR-Cas9 clones mimicking this MLH1 CNV demonstrated that the loss of the regulatory element caused downregulation of both MLH1 and CDH1, suggesting a regulatory crosstalk where MLH1 locus integrity is required for CDH1 expression in the stomach.

C. Oligogenic Deletions Affecting Mucin and Immune Pathways

• Additional Families: In 6 families with particularly young-onset disease, multiple deletions of stomach-accessible chromatin sequences were found outside the CDH1 TAD and classic tumor risk genes.
• Impact: These oligogenic deletions specifically impaired mucin genes and immune-related pathways, favoring a gastric immune-deficient phenotype that predisposes to cancer.

4. Significance

• Solving Missing Heritability: By integrating stomach-specific chromatin accessibility (ATAC-seq), promoter interactions (4C-seq), and WGS, the study resolved the genetic cause in nearly half of previously unexplained HDGC-like families.
• Clinical Implications: The discovery of non-coding CNVs and regulatory element deletions provides actionable targets for genetic counseling. Families previously deemed "negative" can now be identified as high-risk, allowing for prophylactic gastrectomy or intensive surveillance.
• Mechanistic Insight: The study expands the understanding of gastric carcinogenesis beyond coding mutations, highlighting the critical role of:
  1. Tissue-specific enhancers within TADs.
  2. Long-range regulatory interactions between distinct loci (e.g., MLH1 regulating CDH1).
  3. Oligogenic interactions involving immune and mucin pathways.

In conclusion, this research demonstrates that the "missing heritability" in HDGC is largely driven by structural variants affecting non-coding regulatory landscapes, necessitating a shift from exome-only analysis to comprehensive whole-genome and epigenomic profiling for accurate diagnosis.